More recently, in vivo, prostate cancer cells expressing prostate-specific membrane antigen (PSMA) have been successfully targeted with optimized aptamer–siRNA chimeras resulting in pronounced regression of PSMA-expressing tumors in athymic mice after systemic administration (Dassie et al., 2009). This evidence concerns the gene FOLH1 and prostate carcinoma.